ALUMIS INC.
ALMSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ALMS. That does not mean none is planned.
Get an email about ALMS's next catalysts
Track ALUMIS (ALMS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
ALMS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.73 | FQ end Sep/2026 | Call: tbd
How ALMS's past catalysts played out
Market Overview
Stock performance and key metrics
Open-Label ESK-001
Plaque Psoriasis
ESK-001
Plaque Psoriasis
Apremilast
Plaque Psoriasis
Envudeucitinib
SLE
Open-Label Envudeucitinib
Plaque Psoriasis
Blinded Envudeucitinib
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open-Label ESK-001 | Phase 3 | Plaque Psoriasis | - | - |
ESK-001 | Phase 3 | Plaque Psoriasis | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
Envudeucitinib | Phase 3 | SLE | - | - |
Open-Label Envudeucitinib | Phase 3 | Plaque Psoriasis | - | - |
Blinded Envudeucitinib | Phase 3 | Plaque Psoriasis | - | - |
Frequently asked questions
What is in ALUMIS INC.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in ALUMIS INC.'s (ALMS) pipeline across Phase 3. Its lead program is Apremilast (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALUMIS INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ALUMIS INC. (ALMS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALMS biotech catalysts?→
Add ALMS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALUMIS INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.